亚太药业前三季净利9719.5万元，同比增长2909.49%

Core Viewpoint - Asia-Pacific Pharmaceutical (002370) reported a significant increase in net profit due to the sale of a subsidiary, despite a decline in revenue [1] Financial Performance - The company achieved an operating revenue of 228 million yuan in the first three quarters, a year-on-year decrease of 25.59% [1] - The net profit attributable to shareholders reached 97.195 million yuan, marking a year-on-year increase of 2909.49% [1] - The non-recurring net profit was -56.5853 million yuan, reflecting a year-on-year decline of 150.47% [1] Key Events - The substantial increase in net profit was primarily attributed to the sale of 100% equity in its wholly-owned subsidiary, Shaoxing Xingya Pharmaceutical Co., Ltd., which contributed approximately 149 million yuan to the total profit [1]